NBIX vs. WST: Neurocrine Biosciences vs. West Pharmaceutical Services Stock Comparison

Company Profile

Neurocrine Biosciences (NBIX) and West Pharmaceutical Services (WST) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but NBIX is classified in Biotechnology while WST is classified in Life Sciences Tools & Services.

Price Performance

Cumulative Growth

Trailing Returns

Calendar-Year Returns

Performance Metrics

Risk Profile

Drawdown History

Return Distribution

Risk Metrics

Risk-Adjusted Performance

Risk-Return Positioning

Risk-Adjusted Metrics

Profitability

Both Neurocrine Biosciences (NBIX) at 20.42% and West Pharmaceutical Services (WST) at 21.23% sit in the top peer quartile for ROE, suggesting each generates more profit from shareholders’ equity than typical industry peers.

Both Neurocrine Biosciences (NBIX) at 18.98% and West Pharmaceutical Services (WST) at 18.81% keep an unusually large share of revenue as bottom-line profit — each net margin clears its industry’s benchmark range.

Both Neurocrine Biosciences (NBIX) at 31.98% and West Pharmaceutical Services (WST) at 25.37% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.

Profitability Metrics

Growth

Both Neurocrine Biosciences (NBIX) at 21.45% and West Pharmaceutical Services (WST) at 6.25% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.

Both Neurocrine Biosciences (NBIX) at 41.95% and West Pharmaceutical Services (WST) at 1.49% land near their industries' usual EPS growth ranges, so bottom-line momentum looks broadly in line with peers on both sides.

Growth Metrics

Financial Strength

West Pharmaceutical Services (WST) at 2.82 keeps current ratio within its industry’s typical mid-range, while Neurocrine Biosciences (NBIX) at 2.04 runs in the tighter-liquidity quartile — a thinner cushion against current liabilities for NBIX.

Both Neurocrine Biosciences (NBIX) at 0.12 and West Pharmaceutical Services (WST) at 0.11 fund their balance sheets with roughly industry-typical debt-to-equity mixes.

Financial Strength Metrics

Dividends

Neurocrine Biosciences (NBIX) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile West Pharmaceutical Services (WST) reports a yield of 0.22%, ranking against industry peers normally.

Neurocrine Biosciences (NBIX) pays no dividend (payout 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile West Pharmaceutical Services (WST) reports a payout of 9.88%, ranking against industry peers normally.

Dividend Metrics

Valuation

Neurocrine Biosciences (NBIX) at 24.43 is near its industry’s usual P/E ratio, while West Pharmaceutical Services (WST) at 44.87 sits in the richer quartile — WST needs stronger growth or earnings quality to justify the premium.

On P/S ratio, both Neurocrine Biosciences (NBIX) at 4.50 and West Pharmaceutical Services (WST) at 8.20 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.

Neurocrine Biosciences (NBIX) at 4.30 is valued about in line with its industry on P/B ratio, while West Pharmaceutical Services (WST) at 9.40 carries an above-peer premium to book — WST is pricier on assets.

Valuation Metrics